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Metastatic renal cell carcinoma (RCC) has historically been refractory to cytotoxic and hormonal agents; only interleukin 2 and
interferon alpha provide response in a minority of patients. We reviewed RCC biology and explored the ways in which this
understanding led to development of novel, effective targeted therapies. Small molecule tyrosine kinase inhibitors, monoclonal
antibodies and novel agents are all being studied, and phase II studies show promising activity of sunitinib, sorafenib and bevacizumab.
The results of phase III studies will determine the role of these agents in metastatic RCC.
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Malignant renal cell carcinoma (RCC) accounts for 2–3% of
cancer incidence and results in over 100000 worldwide deaths
annually. In developed nations the average age-adjusted incidence
of RCC is approximately 12/100000 in men and 5/100000 in
women. RCC is the most lethal urologic cancer and the sixth
leading cause of cancer deaths in the developed nations. For
reasons that are unclear, RCC age-adjusted incidence has been
rising for the past 30 years within the US and most European
nations at an annual rate of approximately 3% (Chow et al, 1999).
For those who present with metastasis, the overall clinical course
of RCC varies; approximately 50% of patients survive o1 year and
10% survive for over 5 years (Motzer et al, 2004). For those who
present with early stage disease, radical nephrectomy is the
treatment of choice; however, 30% of these patients will relapse
and develop future metastasis. Chemotherapy has consistently
been an ineffective form of treatment for RCC (Motzer et al, 1996),
and until recently, the only effective treatment for metastatic
disease was cytokine-based immunotherapy with interferon
(IFN)-a or interleukin (IL)-2, which have a response rate of
approximately 15% (Rosenberg et al, 1987). Recent advances in
understanding the biology and genetics of RCC have led to several
novel targeted approaches for the treatment of metastatic RCC,
with higher response rates.
RCC GENETICS
Consistent with the multistep carcinogenesis model, RCC is
thought to arise from a complex set of events during which the
tumour cells encounter a variety of selection forces. During this
evolution process, renal cancer cells acquire ‘attributes’ that allow
for an ability to resist exogenous growth-inhibitory signals, to
evade apoptosis, to proliferate without limits (i.e., to undergo
immortalisation), to thrive in a low-oxygen environment, to avoid
immunosurveillance, to recruit angiogenic factors, to invade the
basement membrane, and ultimately to spread to distant sites
(Hahn and Weinberg, 2002). During this multistep process, the
genome of the evolving cell acquires mutations within proto-
oncogenes, tumour-suppressor genes, and other genes that
regulate cell replication and growth (Loeb, 1991). Thus, oncogen-
esis can be viewed as an evolutionary process associated with
multiple rounds of mutation, coupled with selection for specific
‘attributes’. Multiple lines of evidence, including conventional
cytogenetic analysis, spectral karyotype studies, and comparative
genome hybridisation analysis show that RCC cells exhibit
extensive genetic heterogeneity (Pavlovich et al, 2003; Pavlovich
and Schmidt, 2004). Identification of sentinel mutations driving
carcinogenesis and malignant transformation is crucial for
developing targeted therapeutic strategies.
RCC has several histologic types, each arising from distinct
regions of the renal epithelia, caused by a distinct set of gene
mutations and exhibiting a unique clinical course. The most
common types of epithelial renal tumours include: clear-cell renal
carcinoma (75%), type 1 (5%) and type 2 (10%) papillary,
chromophobe (5%), and oncocytoma (5%) (Motzer et al, 1996).
Both sporadic and inherited forms of clear-cell RCC are strongly
associated with mutations in the von Hippel–Lindau (VHL) gene.
In familial VHL-related RCC, the inheritance pattern is autosomal
dominant (Latif et al, 1993). This pattern is consistent with the
Knudson’s ‘two hit’ model, which states that (if an inherited
malignancy is dependent on inactivating mutation of a tumour-
suppressor gene) one copy of the defective gene is inherited and
the second copy is mutated during development/growth, sub-
sequently leading to a more rapid oncogenic transformation
(Knudson, 1971).
Other RCC histologies are also associated with specific
mutations. For example, type 1 papillary RCC is characterised by
mutations in the tyrosine kinase domain of c-Met oncogene, while
mutations in the fumarate hydratase gene of the Krebs cycle have
been found in hereditary leiomyomatosis RCC, an inherited form
of type 2 papillary RCC. Birt–Hogg–Dube ´ syndrome, associated
with loss of function mutation of BHD gene, predisposes affected
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see Linehan et al, 2004). It is currently not known (and subject to
intense study) how individual sets of gene changes lead to cancers
only in specific cell and tissue types. Presumably, multiple other
mutations and epigenetic changes function in concert with the
above-mentioned sentinel mutations to drive the malignant
phenotype. In this review, we focus on recent advancements in
clear-cell RCC, discussing advancements in the understanding of
its biology and subsequent development of effective targeted
therapy.
Clear cell RCC is a highly vascular tumour arising from
epithelial elements within proximal tubules of nephrons. An early
event during the evolution of clear-cell RCC is loss of function
mutation of the VHL gene (Latif et al, 1993). Individuals who
inherit one defective copy of the VHL gene have a substantial risk
for developing a variety of neoplasias, and in these patients the
specific type of VHL mutation (e.g., types of missense, frameshift,
deletion, etc) can influence the risk and type of tumour
development (for review see Kim and Kaelin, 2004). Approxi-
mately 40% of patients with inherited VHL syndrome expire from
complications of metastatic RCC. The renal tumours are of clear-
cell histology, typically occur at a young age, and are characterised
by the presence of multiple primary tumours and ‘premalignant’
cysts located in both kidneys. In contrast, patients with sporadic
clear-cell RCC typically have a single primary lesion. Direct
sequencing experiments form these sporadic tumour samples show
up to 75% of these patients have biallelic loss of function mutation
of VHL genes, and up to 20% exhibit expression inactivation by
hypermethylation (Herman et al, 1994). Currently, it is unknown if
prognosis in patients with sporadic RCC is related to the type of
VHL mutation/alteration. Understanding the function of VHL has
contributed to development of novel therapeutic strategies.
VHL FUNCTION
The VHL gene is located on chromosome 3p25–26 (Latif et al,
1993), and functions in the hypoxia-inducible pathway (Figure 1).
Early investigations showed the VHL gene product is found in a
multiprotein complex composed of Elongin B, Elongin C, Cul2,
and Rbx1 (Kamura et al, 1999). Sequence comparison showed that
Elongin C and Cul2 is homologous to yeast proteins Skp1 and
Cdc53, which form the so-called SCF complex (Skp1, Cdc53, and
F-box protein). This complex of proteins function in yeast in
ubiquitination, a process that ‘marks’ the targeted protein for
degradation by proteosomes (Kamura et al, 1999). Biochemically
purified VHL complex was subsequently shown to have ubiqui-
tination activity. Specifically, the VHL complex ubiquitinates
transcriptional factor hypoxia-inducible factor (HIF)-1a (Kamura
et al, 2000). The normal function of HIF-1 complex (a heterodimer
composed of a and b subunits) is to regulate expression of several
genes in response to hypoxic stress (Wang and Semenza, 1993).
Human cells respond to hypoxic conditions through a series of
pathways, many of which are mediated by HIF-1 (Figure 1). Under
normal conditions (i.e., with wild-type VHL and normal oxygen
tension), HIF-1a is enzymatically hydroxylated at two proline
residues located in the ‘oxygen-dependent degradation domain’.
X-ray crystallography studies with VHL complexed with HIF-1a
confirm this hydroxylation allows for hydrogen bond-mediated
complex formation between the two proteins (Hon et al, 2002).
HIF-1a is subsequently ubiquinated by the VHL complex and
ultimately degraded within proteosomes. Under hypoxic condi-
tions HIF-1a is not hydroxylated, and thus cannot bind and be
efficiently ubiquitinated by the VHL protein complex. Biallelic
inactivation of VHL would likewise prevent ubiquitination and
ultimate degradation of HIF-1a. In addition to regulation by VHL
complex, HIF-1 activity is regulated by growth factor and cell
adhesion pathways. For example, upon binding of a growth factor
to a tyrosine kinase receptor, HIF-1a protein levels increase
through at least three pathways: (1) phosphatidylinositol 3-kinase-
AKT-mammalian target of rapamycin (mTOR) pathway and (2)
Ras/Raf/Map kinase pathway. Lastly, integration-mediated stimu-
lation can also increase HIF-1a levels via PI3K/AKT-mTOR
pathway (Figure 2; for a review see Bardos and Ashcroft, 2004).
Once stabilised, HIF-1a translocates into the nucleus where it
complexes with the constitutively present HIF-1b to form the
active transcriptional factor HIF-1 heterodimer. HIF-1 binds to a
variety of additional transcriptional cofactors, forming a preinitia-
tion complex of proteins that ultimately activates transcription of
hypoxia-inducible genes including: vascular endothelial growth
factor (VEGF; leading to angiogenesis; (Shweiki et al, 1992)),
epidermal growth factor receptor (EGFR; leading to cell growth),
platelet-derived growth factor (PDGF), glucose transporters (e.g.,
GLUT-1), transforming growth factor-a (TGF-a, ligand for EGFR)
and erythropoietin (Bardos and Ashcroft, 2004). Many of these
proteins are involved in angiogenesis, survival, pH regulation, and
glucose metabolism. As mentioned above, the multistep model for
carcinogenesis states that many of these properties are ‘acquired’
during tumour evolution (Loeb, 1991; Hahn and Weinberg, 2002).
Phenotypically, RCC is a highly vascular tumour, with increased
VEGF level, and its growth can be stimulated by factors produced
through the HIF-1 pathway. This molecular biology understanding
has facilitated the development of several therapeutic agents for
RCC.
SUNITINIB
SU11248 (Sunitinib) is an orally bioavailable small molecule that
inhibits multiple split kinase domain receptor tyrosine kinases
(RTKs) in tissue culture and in vitro experiments (including VEGF
receptor 1 and 2, PDGF receptor a and b, KIT receptor, and FLT3
receptor (Mendel et al, 2003; Fabian et al, 2005)). A general model
of how RTKs function includes: a growth factor first ligands to the
extracellular portion of a specific RTK (Figure 2). The RTKs found
at increased levels in RCC include: VEGF receptor, PDGF receptor,
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Figure 1 VHL and HIF-1 pathways. The VHL complex (composed of
von Hippel–Lindau protein, elongin B, elongin C, Cul2, and Rbx1) functions
to regulate levels of hypoxia-inducible factor (HIF)-1a. During normoxia,
HIF-1a is hydroxylated at two proline residues via an oxygen-dependent
enzymatic mechanism. The VHF complex binds to the hydroxylated HIF-1a
and polyubiquinates HIF-1a, leading to proteosome-mediated degradation
of HIF-1a. During hypoxia, HIF-1a is not hydroxylated, and thus cannot
bind with the VHL complex. HIF-1a accumulates and binds to HIF-1b, thus
forming the HIF-1 complex, which subsequently translocates into the cell
nucleus where it binds with hypoxia-responsive element (HRE) in gene
promotors and facilitates expression of hypoxia-inducible genes. Similarly,
loss of function mutations of VHL prevents ubiquitin-mediated degradation
of HIF-1a, resulting in upregulation of hypoxia-inducible genes.
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respectively. Subsequent to ligand binding, the receptor dimerises,
and the intracellular C-terminal tyrosine residues of RTKs are
phosphorylated. This step activates the kinase domain and initiates
a signal transduction cascade that ultimately results in increased
expression of several target genes (Figure 2; for a review see Krause
and Van Etten, 2005). Inhibition of specific tyrosine kinases has
been shown to be effective in treating several cancers that are
‘dependent’ on the TK pathway for proliferation/survival, includ-
ing: chronic myelogenous leukaemia, gastrointestinal stromal
tumours, breast cancer, and a subset of non-small-cell lung cancer.
Sunitinib was created by rational drug design and inhibits tyrosine
kinase activity of multiple split kinase domain RTKs by
competitively binding with ATP at the tyrosine kinase active site.
In a phase I trial, sunitinib showed partial response to several
tumours including RCC and gastrointestinal stromal tumours. In
these initial studies, the agent was well tolerated, and fatigue was
the dose-limiting side effect (Raymond et al, 2003). A regimen of
50mg daily for 4 weeks, followed by 2 weeks off was recommended
for phase II investigation (Table 1). In a phase II study with 63
cytokine-refractory metastatic RCC patients, 40% of patients had a
partial response and 27% had stable disease for at least 3 months;
the median time to progression was nearly 9 months (Motzer et al,
2005). Patients were also monitored for ‘molecular response’ by
measuring biomarker levels of VEGF receptor inhibition, including
plasma concentration of VEGF-A, VEGF-receptor 2, and PDGF.
Interestingly, inhibition of the tyrosine kinase receptors resulted in
decreased VEGF-receptor 2 levels during days 1–28 and con-
comitantly increased ligand levels during days of treatment (days
1–28), with some recovery of levels during the 2-week rest period.
The clinical significance of this effect by the drug on the
downstream elements of the VHL/HIF pathway is under investiga-
tion. Computed tomography imaging of responders shows findings
consistent with necrosis, and it is likely that this agent has direct
cytotoxic effects on tumour cells in addition to potentially
inhibiting neovascularisation (Motzer et al, 2005).
A follow-up phase II trial completed accrual in 11/04 with 106
patients, and preliminary results are available (as of May 2005;
Table 1). Notable difference between the two phase II trials: The
second was limited to patients with clear-cell metastatic RCC,
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Figure 2 Overview of signal transduction pathways and role of selective inhibitors. Binding of a ligand (e.g., VEGF) to two adjacent receptors results in an
active tyrosine kinase (e.g., VEGFR). The receptor tryosine kinase initially undergoes self-phosphorylation at specific tyrosine residues; this results in
stimulation of several pathways. For example, RTKs can stimulate the Ras/Raf/MEK pathway, as the phosphotyrosines of RTKs facilitate docking of Grb2–
SOS complex, ultimately resulting in activation of Ras. The activated Ras binds to Raf-1; afterwards, Raf-1 is activated via a complex series of phosphorylation
and dephosphorylation steps. Ultimately, this pathway regulates expression of genes controlling apoptosis and cell proliferation. Similarly, mTOR is stimulated
by a phosphorylation cascade, which involves proteins including PI3K and AK2. Once stimulated, mTOR controls protein translation of elements involved in
cell cycle progression; in addition mTOR also controls protein synthesis in response to environmental change and starvation (including synthesis of HIF-1a in
RCC cells). The signal transduction pathways can be inhibited at several steps including: (1) inhibition of VEGF (by bevacizumab); (2) inhibition of tyrosine
kinase activity of RTK (by sunitinib and sorafenib); (3) inhibition of Raf kinase (by sorafenib); (4) inhibition of mTOR (by CCI-779).
Table 1 Clinical trials involving targeted agents for RCC
Agent
No. of
patients
Overall
response
a
(%)
Time to
progression
(months)
Sunitinib
Phase II 63 40 8.7
Sorafenib
Phase III 335 2 6.0
Bevacizumab
High-dose arm 39 10 4.8 (Po0.001
vs placebo)
Bevacizumab and erlotinib 59 25 11.1
CCI-779 and IFNa 71 11 9.1
aSummation of partial and complete response based on response evaluation criteria
in solid tumours (RECIST).
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papillary cell subtype. The overall response rate was similar,
confirming the high response rate observed in the first trial. An
international randomised phase III trial of sunitinib (administered
in repeated cycles of 50mg daily for 4 weeks then 2 weeks off) vs
IFN-a (administered three times weekly) has recently completed
accrual; interim analysis results will be available soon.
In the two phase II trials, sunitinib has been generally well
tolerated, with compliance rate during the first 6 months of
treatment of at least 95%; fatigue is the most common dose-
limiting effect (incidence of grade 2–3 fatigue from the phase II
trial is 38%). Other grade 2 or 3 side effects include diarrhoea
(24%), nausea (19%), and stomatitis (19%). A rarer complication
includes erythema is the soles of the feet and palms of the hands
(8%); the pathophysiology of this side effect is currently under
investigation.
SORAFENIB
BAY 43–9006 (Sorafenib) is an orally bioavailable small molecule
in the class of bis-aryl ureas that was initially found to potently
inhibit the serine/threonine Raf-1 kinase (which phosphorylates
proteins b-raf and c-raf); in tissue culture experiments, it has also
subsequently been found to inhibit several RTKs including VEGF
receptor-2 and VEGF receptor-3, FLT3 receptor, and PDGF
receptor-b and c-KIT receptor (Wilhelm et al, 2004; Fabian et al,
2005). The Ras/Raf/MEK pathway leads to increased production of
the HIF-1 complex; in addition, this pathway plays a central role in
cell proliferation and apoptosis (Figure 2). The Ras/Raf/MEK
pathway is initially activated following ligand binding with a RTK.
This leads to a signal cascade which results in Ras activation, with
subsequent formation of an active Ras/Raf protein complex;
following propagation of this cascade, the final effect is upregula-
tion of genes associated with cell proliferation and angiogenesis
(Sebolt-Leopold and Herrera, 2004).
In a phase I trial, sorafenib had activity in a small sample of RCC
patients (n¼11) and a dose of 400mg twice a day was found to be
generally well tolerated (Strumberg et al, 2005). In a recently
completed phase II study, 202 patients with metastatic clear-cell
RCC were treated with sorafenib 400mg b.i.d. for 12 weeks;
afterwards, RCC patients with stable disease (o25% tumour
shrinkage and o25% tumour growth) were randomised to either
continue BAY43–9006 (n¼32) or receive placebo (n¼33).
Following a 12-week induction, those with 425% tumour
shrinkage continued on sorafenib as part of open-arm (n¼73)
and those with 425% growth (n¼51) were taken off the study. Of
the patients in the stable-disease arm who were randomised to
receive sorafenib, the median progression-free survival was 24
weeks after randomisation, relative to 6 weeks in the placebo group
(Ratain et al, 2005).
Currently, a randomised phase III trial comparing sorafenib vs
placebo is under way involving approximately 900 patients with
metastatic clear-cell RCC. A recent interim analysis (n¼335 in
sorafenib arm and n¼337 in placebo arm) showed the median
duration of progression-free survival was 24 weeks in patients
treated with sorafenib compared to 12 weeks in the placebo group
(Table 1). After at least 6 weeks of treatment, 79% of patients were
progression free in the sorafenib arm (2% with partial response
defined by RECIST criteria and 78% with stable disease, defined as
between 25% reduction and 25% growth), compared to 55% in the
placebo arm (0% with partial response and 55% with stable
disease) (Escudier et al, 2005). The most common side effects
included hand–foot skin reaction (26%), diarrhoea (30%),
alopecia (23%), fatigue (18%), nausea (14%), and hypertension
(8%) (Escudier et al, 2005; Ratain et al, 2005). Together, these data
show that sorafenib shows efficacy in metastatic RCC. The
majority of patients had stable disease with prolonged progres-
sion-free survival, albeit only 2% have a partial response based on
RECIST criteria. Interestingly, the partial response rate of
sorafenib is less relative to that of sunitinib, and the stable disease
rate is similar. The relatively lower partial response rate of
sorafenib may be related to the apparent binding affinity of RTKs
including VEGF-receptor-2 and PDGF-receptor-b is weaker for
sorafenib relative to sunitinib (Fabian et al, 2005).
BEVACIZUMAB/ERLOTINIB
As discussed, RCC is a highly vascular tumour associated with high
VEGF and EGF receptor levels. Early studies attempted to block
tumour vasculature with bevacizumab (Avastin), a recombinant
monoclonal antibody that binds VEGF, thus blocking its inter-
action with the VEGF receptor. A phase II trial comparing placebo
(n¼40), low dose (4.5mgkg
 1 loading dose and 3mgkg
 1 day 7
and every 2 weeks afterward; n¼37) and high dose (15mgkg
 1
loading dose, 10mgkg
 1 on day 7 and every 2 weeks afterward;
n¼39) showed modest partial response (10%) with the high-dose
regimen. Median time to progression was 2.5 months with placebo,
3 months with low dose, and 4.8 months with high-dose
bevacizumab (Yang et al, 2003). As noted above, TGF-a and its
receptor, EGFR, are frequently overexpressed in RCC. However,
single-agent clinical trials in RCC patients with either monoclonal
antibodies or single molecules that block EGFR tyrosine kinase
activity (e.g., with erlotinib) have been disappointing.
A compelling approach is to combine agents that block
important pathways (e.g., inhibit VEGF and EGFR) simulta-
neously. In a recently published phase II trial with bevacizumab
(10mgkg
 1 every 2 weeks) and erlotinib (Tarceva; 150mg daily),
of the 59 evaluable clear-cell RCC patients, 3% had complete
response, 22% partial response, and 61% stable disease following 8
weeks of treatment. The median time to progression was 11
months. The most significant reported side effects of the combined
regimen included hypertension, proteinuria, diarrhoea, and acne-
like rash (Hainsworth et al, 2005). A randomised phase II trial of
bevacizumab alone vs bevacizumab and erlotinib recently com-
pleted accrual. The results are anticipated soon, and will assess the
benefit of combination therapy vs bevacizumab alone. Interest-
ingly, erlotinib was originally shown to be effective in patients with
non—small-cell lung cancer; a large percentage of the patients who
respond to erlotnib have an activating mutation within the EGFR
tyrosine kinase domain (Pao et al, 2004; Tsao et al, 2005). It is
currently unclear if RCC patients who respond to the combination
of erlotinib and bevacizumab similarly have a gain-of-function
mutation within the tyrosine kinase active site and/or if they
simply overexpress EGFR/ligand or VEGF/receptor.
CCI-779 (TEMSIROLIMUS)
Mammalian target of rapamycin is a serine/threonine kinase
involved in the PI3K and AKT pathways (Figure 2). This pathway
is activated upon binding of a growth factor (e.g., VEGF, PDGF) to
a RTK. AKT is inhibited by the tumour-suppressor PTEN; hence
this pathway is activated in tumour cells containing a mutated
PTEN. A downstream effect of this pathway is mTOR phosphor-
ylates a component of the mRNA translation initiation, resulting in
increased translation of several proteins involved in cell cycle
progression; in addition, there is increased translation of HIF-1a.
CCI-779, a derivative of the immunosuppressive agent rapamycin,
forms a complex with FK-506-binding protein-12, and this
complex inhibits mTOR kinase activity (Meric-Bernstam and
Mills, 2004).
Phase I study with CCI-779 showed reversible, tolerable side
effects including acne, mucositis, hyperlipidaemia, asthenia,
diarrhoea, and nausea. Interestingly, immune suppression was
apparently not a major side effect at doses tested. In a phase II
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partial response was seen in 7% and clinical benefit rate (i.e.,
patients who either exhibited a complete response, a
partial response, or had stable disease) for at least 24 weeks was
51%, with median time to progression of 5.8 months (Atkins et al,
2004).
A combination of CCI-779 and IFNa was tested in a phase I/II
trial involving 71 patients with metastatic RCC. The maximum
tolerated dose was CCI-779 15mg IV weekly and IFNa 6 million
units three times weekly. Of the 71 enrolled patients, partial
response was seen in 11% and stable disease in 30%; median time
to progression was 9.1 months (Smith et al, 2004). The most
common side effects included: leukopenia (25%), hyperlipidaemia
(15%), asthenia (13%), AST increase (8%), mucositis (6%),
anaemia (6%), thrombocytopenia (6%), and rash (6%). A phase
III clinical trial comparing CCI-779, IFN-a, or a combination of
both is under way, with results pending.
INSIGHTS FROM CLINICAL TRIAL RESULTS
Characterisation of the VHL and HIF pathways has led to a more
detailed understanding of RCC biology, with subsequent develop-
ment of effective therapy. Many VHL/hypoxia-induced regulated
proteins are RTKs and their ligand; inhibition of RTK(s) shows
promise in treatment of RCC. It is currently unclear whether the
major effect of these agents is through inhibition of RTKs residing
within the tumour cells or the surrounding stromal cells; thus it is
unknown if these agents are directly cytotoxic to cancer cells, or
rather these agents arrest proliferation of tumour stroma (e.g., by
blocking angiogenesis). Our experience with sunitinib is that
responding patients generally exhibit evidence of tumour necrosis
within the first few treatment cycles; although this finding is
consistent with significant direct tumoricidal effect, we do not yet
know the contribution of angiogenesis blockade within these
patients. It should be noted that because these therapeutic agents
inhibit multiple RTKs and pathways, it is difficult to discern which
receptor(s) are the most physiologically relevant in RCC. One
hypothesis is RCC tumour (and surrounding stroma) proliferation
is driven by stimulation of multiple RTK receptors/pathways; thus,
an effective therapeutic agent must simultaneously inhibit multiple
RTKs. Alternatively, perhaps the tumour cells and vascular
endothelial cells are all stimulated by one set of ligand/receptor
pair (i.e., VEGF and its receptor(s)). The most relevant RTK(s) for
RCC growth will likely become more apparent over the next few
years as results from clinical trails and laboratory experiments
mature.
Unfortunately, the clinical response to these agents is not
permanent; rather the time to progression is, on average,
approximately 6–12 months. Tumours adapt; the genes and
mutations responsible for this resistance are unknown. One
thought is, since resistance occurs, these agents may not solely
act on normal endothelial and stromal cells to block angiogenesis;
rather these agents may act directly on the evolving cancer cells
(e.g., to block proliferation signals), and over time, the tumours
mutate and evolve. Consistent with this hypothesis, resistance to
other RTK inhibitors in diverse tumours (e.g., imatinib in chronic
myelogenous leukaemia and erlotinib in non-small-cell lung
cancer) can occur via active site RTK mutations within tumour
cells, such that the binding affinity of the inhibitor is diminished.
Alternatively, assuming that the major action of these agents is
blockage of angiogenesis, the cancer cells may adapt by simply
releasing higher concentration of ‘growth factors’, sufficient to
overcome RTK inhibition by these drugs. Comprehensive studies
to address mechanism of resistance are required to reconcile
between the competing theories.
CONCLUSION AND FUTURE DIRECTIONS
Over the past 5 years, we have witnessed rapid advances in the
understanding of RCC biology. This understanding has translated
into development of therapies with improved clinical response. In
phase II clinical trials these therapies have an overall response rate
approaching 40% (Table 1); in contrast the current standard of
care (IFN-a or IL-2) has a response rate of approximately 10–15%.
We await the results of phase III trials to precisely define the role
of the targeted agents in metastatic clear-cell RCC. Unfortunately,
following targeted therapy, response is not permanent, and not all
patients benefit clinically from these agents. In the near future, we
will attempt to identify molecular markers that are associated with
good clinical response. In addition, efforts will be made to
determine the most effective dosing schemes. These agents will be
given to patients with other forms of renal cancers, including
papillary renal cell cancers, as part of a phase II clinical trial. In
order to further enhance response rates, we look for combination
treatment strategies that concurrently inhibit multiple growth
factor pathways including RTKs (e.g., receptors for VEGF, PDGF,
and EGF), phosphatidylinositol 3-kinase-AKT-mTOR, and Ras/
Raf/Map kinase pathways. In addition, we look for the develop-
ment of specific HIF-1 inhibitors; to our knowledge there are no
reports of an effective HIF-1 inhibitor in animal models.
Ultimately, we expect to learn that the evolution of RCC is not
entirely dependent on HIF-1 and RTKs, and other pathways that
drive clear-cell RCC progression will need to be discovered and
novel inhibitors synthesised and tested clinically.
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